<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medvis</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинская визуализация</journal-title><trans-title-group xml:lang="en"><trans-title>Medical Visualization</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-0763</issn><issn pub-type="epub">2408-9516</issn><publisher><publisher-name>RDS-Media Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.24835/1607-0763-996</article-id><article-id custom-type="elpub" pub-id-type="custom">medvis-1007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>COVID-19</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>COVID-19</subject></subj-group></article-categories><title-group><article-title>COVID-19: сравнение динамики КТ-семиотики легких и биохимических показателей у пациентов в группах с положительным ОТ-ПЦР и трехкратным отрицательным ОТ-ПЦР</article-title><trans-title-group xml:lang="en"><trans-title>COVID-19: comparison lung CT signs and biochemical parameters in the groups of patients with three-time positive RT-PCR and with triple negative RT-PCR test during the period of hospitalization</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1643-6613</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Замятина</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Zamyatina</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ординатор,</p><p>117997, Москва, ул. Большая Серпуховская, 27</p></bio><bio xml:lang="en"><p>resident in the specialty “radiology”,</p><p>house 27, st. Bolshaya Serpukhovskaya, Moscow, 117997</p></bio><email xlink:type="simple">catos-zama@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3825-0868</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Михайлюк</surname><given-names>К. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Mikhailyuk</surname><given-names>K. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ординатор,</p><p>117997, Москва, ул. Большая Серпуховская, 27</p></bio><bio xml:lang="en"><p>resident in the specialty “radiology”,</p><p>house 27, st. Bolshaya Serpukhovskaya, Moscow, 117997</p></bio><email xlink:type="simple">kseniya.mihaylyuk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2013-196X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Курочкина</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Kurochkina</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. физ.-мат. наук, главный специалист Регламентной службы ведения нормативно-справочнойинформации,</p><p>125206, Москва, ул. Добролюбова, 11</p></bio><bio xml:lang="en"><p>PhD, Chief specialist of the Regulatory service for maintaining normative and reference information,</p><p>house 11, st. Dobrolyubova, Moscow, 125206</p></bio><email xlink:type="simple">kurochkina37@rambler.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демидова</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Demidova</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор биол. наук, заведующая клинико-диагностическим отделом,</p><p>117997, Москва, ул. Большая Серпуховская, 27</p></bio><bio xml:lang="en"><p>Doct. of Sci. (Biol.), Heаd of the Clinical Diagnostic Department,</p><p>house 27, st. Bolshaya Serpukhovskaya, Moscow, 117997</p></bio><email xlink:type="simple">demidova@ixv.comcor.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9357-0998</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кармазановский</surname><given-names>Г. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kаrmаzаnovsky</surname><given-names>G. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>член-корр. РАН, доктор мед. наук, профессор, заведующий отделением рентгенологии и магнитно-резонансных исследований с кабинетом ультразвуковой диагностики, 117997 Москва, ул. Большая Серпуховская, д. 27;</p><p>профессор кафедры лучевой диагностики и терапии медико-биологического факультета, 117997 Москва, ул. Островитянова, д. 1</p></bio><bio xml:lang="en"><p>сorresponding member of the Russiаn Асаdemy of Sсienсes, Doct. of Sci. (Med.), Professor, Heаd of X-ray and magnetic resonance studies department with ultrasound, 27, Bol. Serpukhovskaya str., Moscow, 117997;</p><p>Professor of radiology department, 1, Ostrovityanova str., Moscow, 117997</p></bio><email xlink:type="simple">karmazanovsky@ixv.ru</email><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ “Национальный медицинский исследовательский центр хирургии имени А.В. Вишневского” Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.V. Vishnevsky National Medical Research Center of Surgery</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ “Центральный НИИ организации и информатизации здравоохранения” Минздрава РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУ “Национальный медицинский исследовательский центр хирургии имени А.В. Вишневского” Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Vishnevsky National Medical Research Center of Surgery</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБУ “Национальный медицинский исследовательский центр хирургии имени А.В. Вишневского” Минздрава России;&#13;
ФГАОУ ВО “Российский национальный исследовательский медицинский университет имени Н.И. Пирогова” Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>A.V. Vishnevsky National Medical Research Center of Surgery; &#13;
Pirogov Russian national research medical university</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>24</day><month>03</month><year>2021</year></pub-date><volume>25</volume><issue>1</issue><fpage>14</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Замятина К.А., Михайлюк К.А., Курочкина А.И., Демидова В.С., Кармазановский Г.Г., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Замятина К.А., Михайлюк К.А., Курочкина А.И., Демидова В.С., Кармазановский Г.Г.</copyright-holder><copyright-holder xml:lang="en">Zamyatina K.A., Mikhailyuk K.A., Kurochkina A.I., Demidova V.S., Kаrmаzаnovsky G.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://medvis.rdsmedia.ru/jour/article/view/1007">https://medvis.rdsmedia.ru/jour/article/view/1007</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: сравнительная характеристика динамики КТ-семиотики и биохимических показателей анализа крови двух групп пациентов с положительным ОТ-ПЦР и трехкратным отрицательным ОТ-ПЦР и ее осмысление путем сопоставления с уже имеющимися в литературе данными.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. Мы провели ретроспективный анализ КТ-изображений 66 пациентов: первую группу (n1 = 33) составили пациенты, у которых на протяжении госпитализации трижды ОТ-ПЦР (мазок из носоглотки на РНК SARS-CoV-2) был отрицательный (группа I), во вторую группу (n2 = 33) были включены пациенты с трехкратным положительным ОТ-ПЦР (группа II). Важным критерием отбора являлось наличие трех КТ-исследований (первичного КТ при поступлении и двух КТ в динамике) и минимум двух результатов показателей биохимического анализа крови (С-реактивный белок (СРБ), фибриноген, протромбиновое время, прокальцитонин), выполненного в единый промежуток времени ± 5 дней от первого КТ-исследования, при поступлении, и ± 5 дней от последнего КТ. Всего было проанализировано 198 КТ-исследований легких (3 исследования на каждого пациента).</p></sec><sec><title>Результаты</title><p>Результаты. Средний возраст пациентов группы I был 58 ± 14,4 года, группы II – 64,9 ± 15,7 года. Количество дней с момента заболевания до проведения первичного КТ-исследования – 6,21 ± 3,74 дня в группе I, 7,0 (5,0–8,0) дня в группе II, до 2-го КТ – 12,5 ± 4,87 и 12,0 (10,0–15,0) дня, до 3-го КТ – 22,0 (19,0–26,0) и 22,0 (16,0–26,0) дня соответственно. В обеих группах у всех 66 (100%) пациентов при первичном исследовании определялся симптом двустороннего “матового стекла” и у 36 (55%) из 66 отмечалась консолидация легочной ткани. Далее на 1-м динамическом КТ-исследовании “матовое стекло” определялось не у всех: у 22 (67%) из 33 пациентов с отрицательным ОТ-ПЦР (I группа) и у 28 (85%) из 33 с положительным (II группа); процент исследований с симптомом консолидации значительно увеличился – 30 (91%) из 33 в группе I, 32 (97%) из 33 – в группе II и впервые появляются рентгенологические симптомы “обратных изменений” – у 17 (52%) из группы I, у 5 (15%) из группы II. На 2-м динамическом КТ-исследовании “матового стекла” и консолидаций определялось по сравнению с 1-м меньше: у 1 и 27 из группы I (3 и 82%) и у 6 и 30 из группы II (18 и 91%) соответственно, хотя симптом консолидации все равно значительно превалирует. Пик “обратных изменений” рентгенологической картины и начало восстановления легочной паренхимы приходятся на последнее динамическое КТ-исследование – 31 (94%) и 25 (76%) в I и II группах соответственно. То есть в исследуемых группах динамика изменений на компьютерных томограммах легких была практически одинаковой.</p><p>Проанализировав показатели биохимического анализа крови, мы выяснили, что СРБ статистически значимо снизился у 93% (p &lt; 0,001) в группе I, в группе II отмечалось статистически значимое уменьшение значений СРБ у 81% пациентов (p = 0,005). При увеличении КТ-тяжести коронавирусной инфекции на одну степень следует ожидать увеличения СРБ на 41,8 мг/мл. В группе I зафиксировано статистически значимое (p = 0,001) снижение фибриногена у 77% пациентов. Аналогичную динамику этого показателя мы получили в группе II – уменьшение значений фибриногена у 66% пациентов (p = 0,002).</p><p>Такие показатели, как прокальцитонин и протромбиновое время, статистически значимо не изменились в процессе стационарного лечения у пациентов исследуемых групп (p = 0,879 и p = 0,135), что может свидетельствовать о нецелесообразности использования данных показателей при оценке динамики состояния пациентов с подобным течением заболевания. При сравнении исходов изучаемых групп отмечается статистически значимо более высокая летальность в группе II – 30,3%, в группе I – 21,2% (p = 0,043).</p></sec><sec><title>Заключение</title><p>Заключение. Согласно полученным нами данным, течение заболевания значимо не отличается в группах пациентов с положительным ОТ-ПЦР и трехкратным отрицательным ОТ-ПЦР. Отрицательный анализ ОТ-ПЦР может быть связан с индивидуальными особенностями пациентов в виде низкой вирусной нагрузки SARS-CoV-2 в верхних дыхательных путях. Поэтому для постановки диагноза COVID-19 при многократных отрицательных результатах РНК вируса в рото- и носоглотке следует ориентироваться на клиническую и рентгенологическую картины и биохимические показатели в динамике.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Research goal</title><p>Research goal. Comparative characteristics of the dynamics of CT semiotics and biochemical parameters of two groups of patients: with positive RT-PCR and with triple negative RT-PCR. Reflection of the results by comparing them with the data already available in the literature.</p><p>The aim of the study is to compare the dynamics of CT semiotics and biochemical parameters of blood tests in two groups of patients: with positive RT-PCR and with triple negative RT-PCR. We also reflect the results by comparing them with the data already available in the literature.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We have performed a retrospective analysis of CT images of 66 patients: group I (n1 = 33) consists of patients who had three- time negative RT-PCR (nasopharyngeal swab for SARS-CoV-2 RNA) during hospitalization, and group II (n2 = 33) includes patients with triple positive RT-PCR. An important selection criterion is the presence of three CT examinations (primary, 1st CT and two dynamic examinations – 2nd CT and 3rd CT) and at least two results of biochemistry (C-reactive protein (CRP), fibrinogen, prothrombin time, procalcitonin) performed in a single time interval of ± 5 days from 1st CT, upon admission, and ± 5 days from 3st CT. A total of 198 CT examinations of the lungs were analyzed (3 examinations per patient).</p></sec><sec><title>Results</title><p>Results. The average age of patients in the first group was 58 ± 14.4 years, in the second – 64.9 ± 15.7 years. The number of days from the moment of illness to the primary CT scan 6.21 ± 3.74 in group I, 7.0 (5.0–8.0) in group II, until the 2nd CT scan – 12.5 ± 4, 87 and 12.0 (10.0–15.0), before the 3rd CT scan – 22.0 (19.0–26.0) and 22.0 (16.0–26.0), respectively.</p><p>In both groups, all 66 patients (100%), the primary study identified the double-sided ground-glass opacity symptom and 36 of 66 (55%) patients showed consolidation of the lung tissue. Later on, a first follow-up CT defined GGO not in all the cases: it was presented in 22 of 33 (67%) patients with negative RT-PCR (group I) and in 28 of 33 (85%) patients with the positive one (group II). The percentage of studies showing consolidation increased significantly: up to 30 of 33 (91%) patients in group I, and up to 32 of 33 (97%) patients in group II. For the first time, radiological symptoms of “involutional changes” appeared: in 17 (52%) patients of the first group and in 5 (15%) patients of the second one. On second follow-up CT, GGO and consolidations were detected less often than on previous CT: in 1 and 27 patients of group I (3% and 82%, respectively) and in 6 and 30 patients of group II (18% and 91%, respectively), although the consolidation symptom still prevailed significantly . The peak of “involutional changes” occurred on last CT: 31 (94%) and 25 (76%) patients of groups I and II, respectively.So, in the groups studied, the dynamics of changes in lung CT were almost equal.</p><p>After analyzing the biochemistry parameters, we found out that CRP significantly decreased in 93% of patients (p &lt; 0.001) in group I; in group II, there was a statistically significant decrease in the values of C-reactive protein in 81% of patients (p = 0.005). With an increase in CT severity of coronavirus infection by one degree, an increase in CRP by 41.8 mg/ml should be expected. In group I, a statistically significant (p = 0.001) decrease in fibrinogen was recorded in 77% of patients; and a similar dynamic of this indicator was observed in group II: fibrinogen values decreased in 66% of patients (p = 0.002).</p><p>Such parameters as procalcitonin and prothrombin time did not significantly change during inpatient treatment of the patients of the studied groups (p = 0.879 and p = 0.135), which may indicate that it is inappropriate to use these parameters in assessing dynamics of patients with a similar course of the disease. When comparing the outcomes of the studied groups, there was a statistically significant higher mortality in group II – 30.3%, in group I – 21.2% (p = 0.043).</p></sec><sec><title>Conclusion</title><p>Conclusion. According to our data, a course of the disease does not significantly differ in the groups of patients with positive RT-PCR and three-time negative RT-PCR. A negative RT-PCR analysis may be associated with an individual peculiarity of a patient such as a low viral load of SARS-CoV-2 in the upper respiratory tract. Therefore, with repeated negative results on the RNA of the virus in the oro- and nasopharynx, one should take into account the clinic, the X-ray picture and biochemical indicators in dynamics and not be afraid to make a diagnosis of COVID-19. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>COVID-19</kwd><kwd>КТ</kwd><kwd>ОТ-ПЦР</kwd><kwd>вирусная пневмония</kwd><kwd>“матовое стекло”</kwd><kwd>консолидация</kwd><kwd>ретикулярные изменения</kwd><kwd>СРБ</kwd><kwd>фибриноген</kwd><kwd>прокальцитонин</kwd><kwd>протромбиновое время</kwd></kwd-group><kwd-group xml:lang="en"><kwd>COVID-19</kwd><kwd>CT</kwd><kwd>RT-PCR</kwd><kwd>viral pneumonia</kwd><kwd>ground-glass opacity</kwd><kwd>consolidation</kwd><kwd>reticular changes</kwd><kwd>CRP</kwd><kwd>fibrinogen</kwd><kwd>procalcitonin</kwd><kwd>prothrombin time</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Guan W.J., Ni Z.Y., Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020; 382: 1708–1720. https://doi.org/10.1056/NEJMoa2002032</mixed-citation><mixed-citation xml:lang="en">Guan W.J., Ni Z.Y., Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020; 382: 1708–1720. https://doi.org/10.1056/NEJMoa2002032</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020.</mixed-citation><mixed-citation xml:lang="en">WHO Director-General’s opening remarks at the media briefing on COVID-19 – 11 March 2020.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020; 383: 2255–2273. http://doi.org/10.1056/NEJMra2026131</mixed-citation><mixed-citation xml:lang="en">Fajgenbaum D.C., June C.H. Cytokine Storm. N. Engl. J. Med. 2020; 383: 2255–2273. http://doi.org/10.1056/NEJMra2026131</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr. 2020; 87 (4): 281–286. http://doi.org/10.1007/s12098-020-03263-6</mixed-citation><mixed-citation xml:lang="en">Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J. Pediatr. 2020; 87 (4): 281–286. http://doi.org/10.1007/s12098-020-03263-6</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Coronavirus disease (COVID-19) Situation dashboard.</mixed-citation><mixed-citation xml:lang="en">Coronavirus disease (COVID-19) Situation dashboard.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Methodological recommendations of the Ministry of Health of the Russian Federation dated 09/03/2020 “Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)” dated 09/03/2020.</mixed-citation><mixed-citation xml:lang="en">Methodological recommendations of the Ministry of Health of the Russian Federation dated 09/03/2020 “Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)” dated 09/03/2020.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Oliveira B.A., Oliveira L.C., Sabino E.C., Okay T.S. SARSCoV-2 and the COVID-19 disease: a mini review on diagnostic methods. Rev. Inst. Med. Trop. Sao Paulo. 2020; 62:e44. http://doi.org/0.1590/S1678-9946202062044</mixed-citation><mixed-citation xml:lang="en">Oliveira B.A., Oliveira L.C., Sabino E.C., Okay T.S. SARSCoV-2 and the COVID-19 disease: a mini review on diagnostic methods. Rev. Inst. Med. Trop. Sao Paulo. 2020; 62:e44. http://doi.org/0.1590/S1678-9946202062044</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res. 2020; 7 (1):11. http://doi.org/10.1186/s40779-020-00240-0.</mixed-citation><mixed-citation xml:lang="en">Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y., Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil. Med. Res. 2020; 7 (1):11. http://doi.org/10.1186/s40779-020-00240-0.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Fang Y., Zhang H., Xie J., Lin M., Ying L., Pang P., Ji W. Sensitivity of Chest CT for COVID-19: Comparison to RTPCR. Radiology. 2020; 296 (2): E115-E117. http://doi.org/10.1148/radiol.2020200432.</mixed-citation><mixed-citation xml:lang="en">Fang Y., Zhang H., Xie J., Lin M., Ying L., Pang P., Ji W. Sensitivity of Chest CT for COVID-19: Comparison to RTPCR. Radiology. 2020; 296 (2): E115-E117. http://doi.org/10.1148/radiol.2020200432.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Long C., Xu H., Shen Q., Zhang X., Fan B., Wang C., Zeng B., Li Z., Li X., Li H. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Eur. J. Radiol. 2020; 126: 108961. http://doi.org/10.1016/j.ejrad.2020.108961.</mixed-citation><mixed-citation xml:lang="en">Long C., Xu H., Shen Q., Zhang X., Fan B., Wang C., Zeng B., Li Z., Li X., Li H. Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Eur. J. Radiol. 2020; 126: 108961. http://doi.org/10.1016/j.ejrad.2020.108961.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Miller T.E., Garcia Beltran W.F., Bard A.Z., Gogakos T., Anahtar M.N., Astudillo M.G., Yang D., Thierauf J., Fisch A.S., Mahowald G.K., Fitzpatrick M.J., Nardi V., Feldman J., Hauser B.M., Caradonna T.M., Marble H.D., Ritterhouse L.L., Turbett S.E., Batten J., Georgantas N.Z., Alter G., Schmidt A.G., Harris J.B., Gelfand J.A., Poznansky M.C., Bernstein B.E., Louis D.N., Dighe A., Charles R.C., Ryan E.T., Branda J.A., Pierce V.M., Murali M.R., Iafrate A.J., Rosenberg E.S., Lennerz J.K. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 2020; 34 (10): 13877–13884. http://doi.org/10.1096/fj.202001700RR.</mixed-citation><mixed-citation xml:lang="en">Miller T.E., Garcia Beltran W.F., Bard A.Z., Gogakos T., Anahtar M.N., Astudillo M.G., Yang D., Thierauf J., Fisch A.S., Mahowald G.K., Fitzpatrick M.J., Nardi V., Feldman J., Hauser B.M., Caradonna T.M., Marble H.D., Ritterhouse L.L., Turbett S.E., Batten J., Georgantas N.Z., Alter G., Schmidt A.G., Harris J.B., Gelfand J.A., Poznansky M.C., Bernstein B.E., Louis D.N., Dighe A., Charles R.C., Ryan E.T., Branda J.A., Pierce V.M., Murali M.R., Iafrate A.J., Rosenberg E.S., Lennerz J.K. Clinical sensitivity and interpretation of PCR and serological COVID-19 diagnostics for patients presenting to the hospital. FASEB J. 2020; 34 (10): 13877–13884. http://doi.org/10.1096/fj.202001700RR.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">National Health Commission of the People’s Republic of China (2020). The diagnostic and treatment protocol of COVID-19.China. (chest CT manifistations of new coronavirus disease 2019 (COVID-19): a pictorial rewiew.)</mixed-citation><mixed-citation xml:lang="en">National Health Commission of the People’s Republic of China (2020). The diagnostic and treatment protocol of COVID-19.China. (chest CT manifistations of new coronavirus disease 2019 (COVID-19): a pictorial rewiew.)</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">http://medradiology.moscow/f/luchevaya_diagnostika_koronavirusnoj_infekcii_covid-19_v2.pdf.</mixed-citation><mixed-citation xml:lang="en">http://medradiology.moscow/f/luchevaya_diagnostika_koronavirusnoj_infekcii_covid-19_v2.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bilinska K., Butowt R. Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular Mechanism. ACS Chem Neurosci. 2020; 11 (15): 2152–2155. http://doi.org/10.1021/acschemneuro.0c00406.</mixed-citation><mixed-citation xml:lang="en">Bilinska K., Butowt R. Anosmia in COVID-19: A Bumpy Road to Establishing a Cellular Mechanism. ACS Chem Neurosci. 2020; 11 (15): 2152–2155. http://doi.org/10.1021/acschemneuro.0c00406.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kаrmаzаnovsky G.G., Zamyatina K.A., Stashkiv V.I., Shantarevich M.Yu., Kondratyev E.V., Semenov F.M., Kuznetsova S.Yu., Kozlova A.V., Plotnikov G.P., Popov V.A., Chupin A.V., Gritskevich A.A., Chililov A.M., Pechetov A.A., Kurochkina A.I., Khokhlov V.A., Kalinin D.V. CT diagnostics and monitoring of the course of viral pneumonia caused by the SARS-CoV-2 virus during the work of the “COVID-19 Hospital”, based on the Federal Specialized Medical Scientific Center. Medical Visualization. 2020; 24 (2): 11– 36. https://doi.org/10.24835/1607-0763-2020-2-11-36</mixed-citation><mixed-citation xml:lang="en">Kаrmаzаnovsky G.G., Zamyatina K.A., Stashkiv V.I., Shantarevich M.Yu., Kondratyev E.V., Semenov F.M., Kuznetsova S.Yu., Kozlova A.V., Plotnikov G.P., Popov V.A., Chupin A.V., Gritskevich A.A., Chililov A.M., Pechetov A.A., Kurochkina A.I., Khokhlov V.A., Kalinin D.V. CT diagnostics and monitoring of the course of viral pneumonia caused by the SARS-CoV-2 virus during the work of the “COVID-19 Hospital”, based on the Federal Specialized Medical Scientific Center. Medical Visualization. 2020; 24 (2): 11– 36. https://doi.org/10.24835/1607-0763-2020-2-11-36</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gupta-Wright A., Macleod C.K., Barrett J., Filson S.A., Corrah T., Parris V., Sandhu G., Harris M., Tennant R., Vaid N., Takata J., Duraisingham S., Gandy N., Chana H., Whittington A., McGregor A., Papineni P. False-negative RT-PCR for COVID-19 and a diagnostic risk score: a retrospective cohort study among patients admitted to hospital. BMJ Open. 2021; 11 (2): e047110. http://doi.org/10.1136/bmjopen-2020-047110</mixed-citation><mixed-citation xml:lang="en">Gupta-Wright A., Macleod C.K., Barrett J., Filson S.A., Corrah T., Parris V., Sandhu G., Harris M., Tennant R., Vaid N., Takata J., Duraisingham S., Gandy N., Chana H., Whittington A., McGregor A., Papineni P. False-negative RT-PCR for COVID-19 and a diagnostic risk score: a retrospective cohort study among patients admitted to hospital. BMJ Open. 2021; 11 (2): e047110. http://doi.org/10.1136/bmjopen-2020-047110</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Arevalo-Rodriguez I., Buitrago-Garcia D., SimancasRacines D., Zambrano-Achig P., Del Campo R., Ciapponi A., Sued O., Martinez-García L., Rutjes A.W., Low N., Bossuyt P.M., Perez-Molina J.A., Zamora J. Falsenegative results of initial RT-PCR assays for COVID-19: A systematic review. PLoSOne.2020; 15 (12): e0242958. http://doi.org/10.1371/journal.pone.0242958</mixed-citation><mixed-citation xml:lang="en">Arevalo-Rodriguez I., Buitrago-Garcia D., SimancasRacines D., Zambrano-Achig P., Del Campo R., Ciapponi A., Sued O., Martinez-García L., Rutjes A.W., Low N., Bossuyt P.M., Perez-Molina J.A., Zamora J. Falsenegative results of initial RT-PCR assays for COVID-19: A systematic review. PLoSOne.2020; 15 (12): e0242958. http://doi.org/10.1371/journal.pone.0242958</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng B., Hu J., Zuo X., Chen J., Li X., Chen Y., Yang G., Shi X., Deng A. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. Clin. Microbiol. Infect. 2020; 26 (10): 1400–1405. http://doi.org/10.1016/j.cmi.2020.06.033</mixed-citation><mixed-citation xml:lang="en">Cheng B., Hu J., Zuo X., Chen J., Li X., Chen Y., Yang G., Shi X., Deng A. Predictors of progression from moderate to severe coronavirus disease 2019: a retrospective cohort. Clin. Microbiol. Infect. 2020; 26 (10): 1400–1405. http://doi.org/10.1016/j.cmi.2020.06.033</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Hasanoglu I., Korukluoglu G., Asilturk D., Cosgun Y., Kalem A.K., Altas A.B., Kayaaslan B., Eser F., Kuzucu E.A., Guner R. Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg. Infection. 2021; 49 (1): 117–126. http://doi.org/10.1007/s15010-020-01548-8</mixed-citation><mixed-citation xml:lang="en">Hasanoglu I., Korukluoglu G., Asilturk D., Cosgun Y., Kalem A.K., Altas A.B., Kayaaslan B., Eser F., Kuzucu E.A., Guner R. Higher viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg. Infection. 2021; 49 (1): 117–126. http://doi.org/10.1007/s15010-020-01548-8</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Lee Y.L., Liao C.H., Liu P.Y., Cheng C.Y., Chung M.Y., Liu C.E., Chang S.Y., Hsueh P.R. Dynamics of anti-SARSCov-2 IgM and IgG antibodies among COVID-19 patients. J. Infect. 2020; 81 (2): e55–e58. http://doi.org/10.1016/j.jinf.2020.04.019</mixed-citation><mixed-citation xml:lang="en">Lee Y.L., Liao C.H., Liu P.Y., Cheng C.Y., Chung M.Y., Liu C.E., Chang S.Y., Hsueh P.R. Dynamics of anti-SARSCov-2 IgM and IgG antibodies among COVID-19 patients. J. Infect. 2020; 81 (2): e55–e58. http://doi.org/10.1016/j.jinf.2020.04.019</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
